Cambridge Epigenetix
Cambridge Epigenetix is the Cambridge, UK genomics and epigenetics company founded on the six-base genome — resolving the four canonical DNA bases plus 5-methylcytosine and 5-hydroxymethylcytosine from a single low-input sample in one experiment — and it rebranded to biomodal in 2023. DUPLICATE RECORD: this stub was created from the secondary-market harvest backlog (Forge Global listing) under the company's former name and profiles the same company already held in the API Evangelist network as all/biomodal, which carries the live profile (CLI command surface, domain security, blog archive, screenshots and Kin Score history). The legacy domain cambridge-epigenetix.com now 301-redirects to biomodal.com, so there is no independent Cambridge Epigenetix surface to profile. No API surface has been registered here and no artifacts have been generated, so this record does not split the company across two Kin Scores. It is queued for the duplicate-retirement procedure (survivor: biomodal).
Cambridge Epigenetix is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Genomics, Epigenetics, and Multiomics.
Kin Score
Resources
Company 1
The organization behind the API
Other 1
Properties that don't map to a standard resource type